{"id":"W2597768246","doi":"","title":"Preliminary results of a phase II study of brentuximab vedotin using a response adapted design for the first line treatment of patients with Hodgkin lymphoma unsuitable for chemotherapy due to age, frailty or co-morbidity (BREVITY)","year":2016,"lang":"en","type":"article","venue":"Research Explorer (The University of Manchester)","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"University of Texas MD Anderson Cancer Center; Wojskowy Instytut Medyczny; Universitätsklinikum Köln; Université de Lorraine; Assistance publique-Hôpitaux de Paris; Humanitas University; Aalborg Universitetshospital; Université de Namur; Università di Bologna; Všeobecná Fakultní Nemocnice v Praze; Memorial Sloan-Kettering Cancer Center; Rigshospitalet; Università degli Studi di Firenze; University of California, Los Angeles; Institut National de la Santé et de la Recherche Médicale; Gentofte Hospital; Barbara Ann Karmanos Cancer Institute; University of Toronto; Brigham and Women's Hospital; Emory University; Università Degli Studi di Modena e Reggio Emila; Bristol-Myers Squibb; BC Cancer Agency; Università degli Studi di Pavia; Aalborg Universitet; Univerzita Karlova v Praze","keywords":"Brentuximab vedotin; Medicine; Oncology; Internal medicine; Lymphoma; Chemotherapy; Hodgkin lymphoma","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001057542,0.0002094589,0.0006740439,0.0002559033,0.0002960423,0.000005391063,0.0002992331,0.00006549058,0.00001678027],"category_scores_gemma":[0.0003697494,0.0001063696,0.0001649646,0.0004028165,0.0003239299,0.00009636293,0.0001161852,0.00003306702,8.264382e-7],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004786778,"about_ca_system_score_gemma":0.0004458971,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0001703714,"about_ca_topic_score_gemma":0.00006627189,"domain_scores_codex":[0.9979244,0.0003561096,0.0003798732,0.0003818867,0.0006059348,0.0003518344],"domain_scores_gemma":[0.9940106,0.004073035,0.0003177784,0.0007331854,0.0007454701,0.0001199442],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.7840372,0.06046611,0.008630266,0.0004310457,0.00186378,0.00009880408,0.05549899,0.0001240792,0.003574345,0.000003931455,0.0009540573,0.08431736],"study_design_scores_gemma":[0.2490962,0.324064,0.2996147,0.001647829,0.00106351,0.000007223551,0.01694151,0.0005411726,0.09974305,0.0000151553,0.006991605,0.0002740494],"study_design_candidate":"randomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9892617,0.00006896633,0.002369789,0.001058294,0.00001465013,0.006850071,0.0003650222,0.000009586344,0.000001863266],"genre_scores_gemma":[0.9979484,0.0001442188,0.001689048,0.00001108408,0.00001947897,0.0000768514,0.00001898999,0.00002348409,0.00006842921],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.5349411,"threshold_uncertainty_score":0.4337627,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.2173316733654037,"score_gpt":0.3722261433574812,"score_spread":0.1548944699920776,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}